Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
12,273 total articles
Quantum Cyber N.V. has terminated its at-the-market (ATM) issuance sales agreement with Maxim Group LLC following a strengthened financial position, including over $15 million received from warrant exercises in May 2026. The company is now debt-free with no exercisable warrants outstanding, providing sufficient cash runway to advance its autonomous…
Spectral AI, Inc., a US-based AI medical diagnostics company specializing in wound care, joins the American Board of Wound Management Foundation in celebrating Wound Healing Awareness Month. The company highlights its DeepView System for burn wounds, which recently gained FDA De Novo classification, enabling faster and more accurate treatment decis…
LIXTE Biotechnology Holdings, Inc. announced a definitive agreement to acquire NOMAD Transportable Power Systems, a leader in mobile, utility-grade 1 MW battery energy storage systems (BESS). Post-acquisition, LIXTE will rebrand as NOMAD Power Solutions, shifting focus to address the growing power capacity demand driven by AI, electrification, and …
Park Ha Biological Technology Co., Ltd., listed on NASDAQ as BYAH, has formed a strategic partnership with Star Plus Action, a subsidiary of Hong Kong-listed Star Plus Legend Holdings. The collaboration aims to merge AI technology, skincare product development, celebrity IP management, and health maintenance to innovate the beauty and wellness indu…
OFA Group (Nasdaq: OFAL) announced that Nasdaq has granted it a second 180-day extension, until December 7, 2026, to regain compliance with the minimum $1.00 bid price per share rule. The company remains compliant with all other Nasdaq Capital Market listing standards. OFA may implement a reverse stock split if necessary to meet the requirement. Tr…
KE Holdings Inc. reported that all resolutions presented at its 2026 Annual General Meeting were approved, including amendments to its memorandum and articles of association, the re-election of key directors, and granting of general mandates for share issuance and repurchase. The company remains focused on its integrated online and offline real est…
Cogent Biosciences announced encouraging preclinical results of CGT1145, a novel JAK2 V617F mutant-selective inhibitor, at the 2026 European Hematology Association Congress. The drug showed over 100-fold selectivity for the mutant over wild-type JAK2, with potential to treat myeloproliferative neoplasms while minimizing off-target effects. The comp…
Rezolve Ai's Board of Directors will seek shareholder approval to reduce capital and repurchase up to $300 million of ordinary shares through an agreement with BTIG. The program demonstrates confidence in the company's growth prospects and aims to address what the Board sees as market undervaluation. The repurchases will be funded from cash reserve…
Inspire Medical Systems, a US-based medical device company specializing in innovative treatments for obstructive sleep apnea, announced its management team's participation in the Wells Fargo 2026 MedTech Innovation Spotlight scheduled for June 26, 2026. The company will webcast its presentation, showcasing its proprietary Inspire therapy, an FDA an…
Independent Bank Corporation (NASDAQ: IBCP) announced it has received regulatory approval from the Federal Reserve Bank of Chicago and the Michigan Department of Insurance and Financial Services to acquire HCB Financial Corp., the parent company of Highpoint Community Bank. The merger, pending HCB shareholder approval, is expected to close July 1, …
Profusa, Inc. announced the submission of its response to the European notified body GMED as part of the ongoing Medical Device Regulation (MDR) conformity assessment for its Lumee Oxygen Platform. This milestone advances the company's efforts to obtain CE Mark certification, critical for commercializing its real-time tissue oxygen monitoring biose…
UniFirst Corporation announced that more than 99% of shareholders approved its acquisition by Cintas Corporation. Under the agreement, UniFirst shareholders will receive $155 per share in cash plus 0.7720 shares of Cintas stock. The transaction is expected to close in the second half of 2026, pending customary conditions and regulatory approvals. T…
Kalaris Therapeutics announced the presentation of Phase 1a clinical trial data for its lead asset TH103, a novel dual-targeting biologic for neovascular Age-Related Macular Degeneration (nAMD), at Clinical Trials at the Summit 2026. The data demonstrates early safety and efficacy signals. TH103, designed by noted VEGF scientist Dr. Napoleone Ferra…
BrightSpring Health Services, a NASDAQ-listed provider of home- and community-based pharmacy and health services, announced the appointment of Dr. Nigam H. Shah, a leading expert in biomedical data science and artificial intelligence in healthcare, to its Board of Directors. Dr. Shah will also join the Quality and Compliance Committee, bringing val…
Cogent Biosciences reported detailed and updated clinical data from its pivotal APEX trial of bezuclastinib in patients with advanced systemic mastocytosis (AdvSM), demonstrating a high objective response rate, robust disease pathology improvements, and a favorable safety profile. The company plans an NDA submission in June 2026 and anticipates FDA…
3 E Network Technology Group Limited, a Nasdaq-listed B2B IT business solutions provider, announced its strategic roadmap to become a next-generation AI infrastructure provider focusing on robotics. CEO Dr. Tingjun Yang emphasized advancing edge AI through silicon hardware innovation, hardware-software co-design, and building a scalable computing p…
Scilex Holding Company (Nasdaq: SCLX), a US-based biopharmaceutical company specializing in non-opioid pain management products, has confirmed the payment date of June 15, 2026, for a dividend of Semnur Pharmaceuticals, Inc. (OTC: SMNR) common stock to its shareholders. Eligible holders as of June 1, 2026, will receive one share of Semnur common st…
CervoMed Inc., a clinical-stage biotech company focused on treatments for age-related brain disorders, announced its management will participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit. The company highlighted progress on its lead drug candidate, neflamapimod, including recent completion of Phase 2b trials in dementia wit…
United Community Banks, Inc. announced a definitive agreement to sell its equipment finance business, Navitas Credit Corp. and NLFC Reinsurance Corp., to funds managed by Wafra Inc. for $1.9 billion in cash. The transaction is expected to enhance United's liquidity and capital strength, reduce risk in its loan portfolio, and allow greater focus on …
Exodus Movement, Inc. announced the launch of Exodus Markets, a new platform allowing customers to directly buy and sell over 200 tokenized stocks, ETFs, and real-world assets on the Solana blockchain. This move further expands Exodus from a self-custodial wallet provider into a comprehensive financial platform offering trading, spending, rewards, …
Fervo Energy, a NASDAQ-listed independent power producer specializing in Enhanced Geothermal Systems, will report its first quarter 2026 financial and operational results on June 22, 2026, with a webcast and conference call scheduled to discuss the details. The company emphasizes its role in advancing clean, reliable geothermal energy to meet incre…
Village Farms International, Inc. announces the launch of the Pure Sunfarms Pink Kush Cured Resin 510 Vape in Canada, extending their top-selling Pink Kush strain into the rapidly expanding vape segment. The product offers a true-to-flower experience with premium cured resin, aiming to capture growth in the Canadian cannabis vape market, which is t…
MBX Biosciences released one-year data from its ongoing open-label extension study of once-weekly canvuparatide in chronic hypoparathyroidism patients, showing sustained responder rates, normalization of calcium levels, improved kidney function, and bone metabolism restoration with good tolerance. The Phase 3 trial initiation is on track for Q3 202…
Kymera Therapeutics announced Phase 1 clinical results for KT-621, its first-in-class oral STAT6 degrader, presented at the Japanese Dermatological Association meeting. The study in healthy Japanese adults showed favorable safety, pharmacokinetics, and strong STAT6 degradation consistent with previous data. Parallel Phase 2b trials in atopic dermat…
BioCryst Pharmaceuticals presented new clinical and real-world evidence highlighting the effectiveness of its hereditary angioedema (HAE) portfolio, including ORLADEYO, an oral prophylactic treatment, and investigational monoclonal antibody navenibart. Data demonstrated sustained reductions in HAE attack rates, healthcare utilization, and positive …
